STOCK TITAN
  1. Home
  2. News
  3. ALVO

Alvotech - ALVO STOCK NEWS

Welcome to our dedicated news page for Alvotech (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alvotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alvotech's position in the market.

News
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Rhea-AI Summary
Alvotech, in partnership with Teva Pharmaceuticals, has signed an agreement with a strategic partner to introduce the newly FDA approved high-concentration interchangeable biosimilar to Humira to the U.S. market. This agreement aims to improve patient access to vital biologics in the U.S. and globally. The long-term partnership reflects Alvotech's commitment to providing more affordable healthcare options. Teva Pharmaceuticals will continue to commercialize the biosimilar under the SIMLANDI brand in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Rhea-AI Summary
Alvotech and Teva Pharmaceuticals announce the U.S. FDA approval of SELARSDI, a biosimilar to Stelara, for the treatment of psoriasis and psoriatic arthritis in adults and pediatric patients. SELARSDI is expected to be marketed in the U.S. in 2025, following a settlement agreement with Johnson & Johnson. The approval marks Teva's commitment to expanding biosimilar availability and Alvotech's success in developing biosimilars.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
-
News
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Rhea-AI Summary
Alvotech and Teva receive U.S. FDA approval for SELARSDI, a biosimilar to Stelara, for the treatment of psoriasis and psoriatic arthritis. SELARSDI is expected to be available in the U.S. by February 21, 2025, following a settlement agreement with Johnson & Johnson. The approval marks the second biosimilar approval under the Alvotech-Teva partnership, showcasing a significant opportunity to improve patient access and reduce healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
News
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) increases share capital by issuing 13 million ordinary shares at USD 15.98 per share. Subsidiary holds 7.7% of issued shares. Company aims to meet financial obligations through share capital increase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
none
-
News
CHIPOTLE BURRITOS GO GREEN IN AUGUSTA, GA TO KICK-OFF GOLF'S BIGGEST TOURNAMENT
Rhea-AI Summary
Alvotech reports strong financial results for 2023 with total revenues of $93.4 million, a 10% increase from the previous year. Product revenues in 2023 were $48.7 million, up significantly from $24.8 million in 2022. The company's biosimilar products, including Simlandi™ and Jamteki™, have seen successful launches and approvals in the U.S., Canada, and Europe. Alvotech also achieved positive top-line results from clinical studies for proposed biosimilars to Eylea®, Prolia®/Xgeva®, and Simponi®/Simponi Aria®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
News
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
Rhea-AI Summary
Alvotech (ALVO) schedules a market update audio call with Chief Commercial Officer providing the update. The webcast will be available for replay for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.54%
Tags
none
News
Alvotech Announces Increase in Number of Own Shares
Rhea-AI Summary
Alvotech (ALVO) increases share capital by issuing 13 million ordinary shares at $15.98 per share, with subsidiary holding 7.7% of total shares. The company aims to meet financial obligations through the sale of 10,127,132 ordinary shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.24%
Tags
none
-
News
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Rhea-AI Summary
Alvotech (ALVO) reports a 10% increase in total revenues in 2023, reaching $93.4 million, with product revenues soaring to $48.7 million. Key highlights include FDA approval of Simlandi™ biosimilar to Humira®, launch of Jamteki™ biosimilar to Stelara®, and positive results from clinical studies for proposed biosimilars.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
earnings
-
News
The ONE Group Hospitality, Inc. to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast at 4:30 PM ET on March 14, 2024
Rhea-AI Summary
Alvotech (ALVO) announces the sale of 10,127,132 ordinary shares to investors for approximately USD 166 million. The transaction, valued at USD 16.41 per share, aims to strengthen the company's production capacity and support expected biosimilars launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
conferences earnings
News
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
Rhea-AI Summary
Alvotech, a global biotech company, will release financial results for the full year 2023 and host a Capital Markets Day in Reykjavik on March 22, 2024. The company specializes in biosimilar medicines development and manufacture for patients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
earnings
Stock ALVO logo
Alvotech

Nasdaq:ALVO

ALVO Rankings

#1371 Ranked by Market Cap
#458 Ranked by Stock Gains
N/A Ranked by Dividends

ALVO Stock Data

3.56B
83.10M
72.34%
6.97%
0.07%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Luxembourg
Luxembourg

About ALVO

alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a